Longbow Starts C.R. Bard (BCR) at Neutral
More News related to BCR
- Baird Initiates Coverage on Several Medical Instruments & Supplies Stocks
- C. R. Bard (BCR) Ups Qtr. Dividend by 6% To $0.17, Yielding 0.93%
- Bard Increases Quarterly Dividend
- David Moenning's Daily State of the Markets: 4/23
- Morning Movers 4/23: LNET, TAST, WGOV, ACOR, TTHI, RSH Higher; CNMD, VMW, SANM, NCR, JAKK Lower
Longbow Research initiates coverage on C.R. Bard (NYSE: BCR) with a Neutral rating.
C. R. Bard, Inc. and its subsidiaries engage in the design, manufacture, packaging, distribution, and sale of medical, surgical, diagnostic, and patient care devices worldwide.
Related Categories
New CoverageStocks Mentioned
-46.09Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
